Smo信号增强通过抑制成纤维细胞自噬促进肾脏纤维化
本研究探讨Smo在成纤维细胞活化中的作用。通过成纤维细胞特异性Smo和β-catenin敲除小鼠、原代成纤维细胞及单核RNA测序发现,Smo在CKD成纤维细胞中上调且自噬能力下降;Smo通过β-arrestin1/Src/β-catenin通路诱导mTOR转录抑制自噬,促进肌成纤维细胞活化和纤维化,而Smo拮抗剂NVP-LDE225可恢复自噬并延缓纤维化。
要点
- Smo在多种CKD模型的肾脏成纤维细胞中上调并伴随自噬能力下降。
- Smo通过β-arrestin1/Src/β-catenin通路诱导mTOR转录抑制自噬。
- 成纤维细胞特异性敲除Smo或β-catenin可改善肾脏纤维化。
核心结论
- Smo信号通过抑制成纤维细胞自噬促进肌成纤维细胞活化和肾脏纤维化。
- 靶向成纤维细胞Smo是治疗慢性肾脏病的潜在途径。
研究设计与样本
- 研究使用成纤维细胞特异性Smo和β-catenin敲除小鼠,并分离培养原代肾脏成纤维细胞。
- 采用单核RNA测序联合bulk RNA测序进行分析。
主要发现
- 在人类图谱snRNA-seq数据和小鼠原代成纤维细胞bulk RNA测序中发现,CKD(输尿管梗阻、缺血/再灌注、阿霉素肾病和5/6肾切除模型)中肾脏成纤维细胞Smo上调。
- Shh刺激或Smo过表达使成纤维细胞自噬失活,并加剧肌成纤维细胞增殖和活化。
- 在自噬体蛋白ATG5敲除的成纤维细胞中,这些效应进一步增强。
- Smo通过β-arrestin 1/Src/β-catenin通路诱导mTOR转录,介导成纤维细胞自噬抑制。
- 成纤维细胞特异性敲除Smo或β-catenin可显著保留自噬能力并改善肾脏纤维化。
临床怎么用
- Smo拮抗剂NVP-LDE225在实验中恢复成纤维细胞自噬并延缓纤维化,提示靶向成纤维细胞Smo可能治疗CKD。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Kidney fibrosis progressively induces kidney function loss, leading to kidney failure. Myofibroblast transition from fibroblast is significantly involved in the development of kidney fibrosis. Previous studies revealed that sonic hedgehog (Shh), the upstream ligand of Smoothened (Smo) receptor signaling, contributes to kidney fibrosis. However, the role of Smo in fibroblast activation remains unclear. METHODS: Here, fibroblast-specific Smo and β-catenin knockout mice were generated, primary kidney fibroblasts were isolated and cultured. Single-nucleus (snRNA-seq) plus bulk RNA sequencing were performed. Autophagy capacities, including autophagy flux, autophagy vacuoles, and autophagy-related gene expression, were assessed. RESULTS: From snRNA-seq data of the human atlas combined with bulk RNA sequencing of primary mouse kidney fibroblasts, we discovered Smo was upregulated in kidney fibroblasts in chronic kidney disease (ureteral obstruction, ischemia/reperfusion, Adriamycin nephrosis and 5/6th nephrectomy models). This was accompanied by substantially diminished autophagic capacity. Shh stimulation or ectopic Smo deactivated autophagy, exaggerated myofibroblast proliferation and activation in the fibroblasts. These effects were further enhanced in autophagosome protein ATG5 knockout fibroblasts. Moreover, Smo, through the β-arrestin 1/Src/β-catenin pathway, induced the transcription of mammalian target of rapamycin. This mediated autophagy suppression in fibroblasts, leading to myofibroblast activation and kidney fibrosis. Fibroblast-specific knockout of Smo or β-catenin greatly preserves autophagy capacity and ameliorates kidney fibrosis. Notably, NVP-LDE225, a specific Smo antagonist, effectively restored fibroblast autophagy and retarded kidney fibrotic lesion formation. CONCLUSIONS: Our study defines a prominent mechanism of myofibroblast activation and supplies a potential avenue for targeting fibroblast Smo to treat chronic kidney disease.
引用
- Wang X, Liang Y, Li J, et al. Increased Smoothened signaling promotes kidney fibrosis through inhibiting autophagy in fibroblasts. Kidney Int. 2026. PMID: 41765182. doi:10.1016/j.kint.2026.01.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。